Compare Amgen, Inc. (AMGN) vs Blackrock Inc (BLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Blackrock Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Blackrock Inc trades at $1,034.01 (market cap $160.59B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | BLK | |
|---|---|---|
Market Cap | $196.12B | $160.59B |
Sector | Health | Financials |
52-Week High | $388.16 | $1.20K |
52-Week Low | $271.18 | $922.90 |
Enterprise Value | $241.41B | $162.41B |
Dividend Yield | 2.77% | 2.21% |
Volume | — | 641,547 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BlackRock (BLK) trades at $1,036.11, up 1.61% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with $24.22B revenue and 24.4% net margin. Recent developments include the launch of a new Nasdaq-100 ETF challenging Invesco QQQ, with Q2 2026 earnings expected on July 15.
Outlook remains positive with 76% analyst buy ratings and $1,270 consensus price target representing 22.6% upside. Key risks include market volatility affecting asset management fees and competitive pressure in ETF space. The company's pivot to private markets and AI-driven growth initiatives provide long-term opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →
